Proposed National Coverage Determination Memo by CMS for PRP Gel Issued
- Fri, 5/11/12 - 10:08am
- 0 Comments
- 724 reads
The Centers for Medicare & Medicaid Services (CMS) issued a proposed National Coverage Determination (NCD) memo for autologous blood-derived products for chronic non-healing wounds. In its decision memo, CMS proposed coverage through its Coverage with Evidence Development program for all three major wound categories: diabetic, venous, and pressure wounds.
The release of the proposed NCD memo follows six months of CMS analysis and consideration, subsequent to formal approval of a reconsideration request made by Cytomedix, Inc (Gaithersburg, MD) and several clinical practitioners and industry opinion leaders.
Cytomedix’s comprehensive request for Medicare coverage reconsideration proposed that there is sufficient and compelling clinical evidence to validate the use of autologous PRP gel to treat chronic, non-healing pressure ulcers, venous ulcers, and diabetic foot ulcers. The request sets out the reasons why PRP gel significantly and reliably improves the rate of complete healing, speed and progress to healing, and quality of life as compared with standard wound care in the Medicare-eligible population.
Visit http://www.cytomedix.com for more information.